Related references
Note: Only part of the references are listed.Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
Bastiaan M. Prive et al.
BMC CANCER (2020)
Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis
Finn Edler von Eyben et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression
Louise Emmett et al.
CLINICAL GENITOURINARY CANCER (2019)
Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution
Rhiannon McBean et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2019)
TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Michael S. Hofman et al.
BJU INTERNATIONAL (2019)
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
Finn Edler von Eyben et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Incidence, prevalence, mortality, disability-adjusted life years and risk factors of cancer in Australia and comparison with OECD countries, 1990-2015: findings from the Global Burden of Disease Study 2015
Yohannes Adama Melaku et al.
CANCER EPIDEMIOLOGY (2018)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
Wolfgang P. Fendler et al.
ONCOTARGET (2017)
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
Harshad R. Kulkarni et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Share Paper
